About
Advisor to Lightstone Ventures and CEO of IFM Therapeutics since 2019, with three successful exits generating $750M in realized proceeds and $4B+ in success-based milestones. Martin previously served as Global Head of BD&L at Novartis NIBR and head of the Genomics Institute, advancing 40+ clinical candidates.
Colleagues at Lightstone Ventures
Brendan Kelly
Principal at Lightstone Ventures
Brendan Kelly, Ph.D.
Principal at Lightstone Ventures
Caroline Gaynor
Partner at Lightstone Ventures
Christina Isacson
Partner at Lightstone Ventures
Christina Isacson, Ph.D.
Partner at Lightstone Ventures
Doug Treco
Advisor at Lightstone Ventures
Doug Treco, Ph.D.
Advisor at Lightstone Ventures
Frank D. Lee
Advisor at Lightstone Ventures